TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
WALTHAM, Mass., April 04, 2016 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P. to the Company’s Board of Directors. Dr. Patel has served as a Senior Fellow at The Brookings Institution, as well as a practicing physician at Johns Hopkins since January 2011.
“Dr. Patel brings extensive leadership experience in healthcare policy, healthcare research and patient advocacy to TESARO,” said Lonnie Moulder, CEO of TESARO. “Her expertise will be a valuable resource for the Company in the current healthcare environment as we execute on our mission of providing transformative therapies to people bravely facing cancer.”
Dr. Patel has more than fifteen years of healthcare leadership experience and clinical work, with an emphasis on bridging research, innovation, policy and advocacy. Prior to joining The Brookings Institution, Dr. Patel served as Director of Policy for the Office on Intergovernmental Affairs and Public Engagement at The White House from 2009 to 2010. Prior to that, she served as Deputy Staff Director for Health for Senator Edward M. Kennedy from 2007 to 2009. Currently, Dr. Patel serves as a member of the Board of Directors of SSM Healthcare and Dignity Healthcare, which are nonprofit integrated delivery systems and Community Catalyst, a national advocacy organization. She also serves as an advisory board member for the National Commission of Physician Payment Reform, the Robert Graham Center for Policy Studies in Family Medicine and Primary Care, and the Johns Hopkins Medicine Sibley Hospital Innovation Hub. Dr. Patel earned her Bachelor of Arts degree from the University of Texas at Austin, her M.D. from the University of Texas Health Science Center, and her M.S.H.S. from the University of California, Los Angeles.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com.
Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or [email protected]
